Last reviewed · How we verify
Moderna RSV vaccine
At a glance
| Generic name | Moderna RSV vaccine |
|---|---|
| Sponsor | Emory University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers (PHASE2)
- A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age (PHASE3)
- Systems Biological Analysis of Immune Responses to RSV Vaccine (PHASE4)
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (PHASE3)
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moderna RSV vaccine CI brief — competitive landscape report
- Moderna RSV vaccine updates RSS · CI watch RSS
- Emory University portfolio CI